The Challenge of Antimicrobial Resistance in the Indian Healthcare System

This editorial addresses the escalating challenge of antimicrobial resistance (AMR) in India. It outlines how misuse and overuse of antimicrobials in humans and animals, environmental contamination, and inadequate sanitation are driving resistance. The purpose is to synthesize recent surveillance data and contextual factors across urban and rural settings and private versus public healthcare sectors, and to propose a comprehensive, multisectoral strategy to mitigate AMR. The importance lies in the increasing therapeutic failures and shrinking antibiotic options due to rising resistance rates among key pathogens.

The paper references national surveillance and recent studies: the ICMR Antimicrobial Resistance Surveillance Network Annual Report (2021) documenting declining susceptibility of Klebsiella pneumoniae and Escherichia coli to carbapenems and high carbapenem resistance in Acinetobacter baumannii; a study by Sharma et al. (2023) showing sharp declines in Klebsiella pneumoniae sensitivity to meropenem (2018–2022) and colistin; analyses of community-level antibiotic utilization in India compared to Europe (Farooqui et al., 2018); qualitative work on policy interventions in primary care (Nair et al., 2023); community-level AMR patterns in urban and rural Karnataka (Balachandra et al., 2021); and broader sociopolitical perspectives on AMR in India (Broom and Doron, 2020). It also notes WHO and ICMR initiatives aimed at surveillance, awareness, research, and development of new antimicrobials.

• Surveillance data (ICMR 2021) show significant declines in carbapenem susceptibility: Klebsiella pneumoniae to imipenem fell from 65% (2016) to 43% (2021); Escherichia coli to imipenem fell from 86% (2016) to 64% (2021). Carbapenem-resistant E. coli and K. pneumoniae often showed co-resistance to multiple drugs. Acinetobacter baumannii was carbapenem-resistant in 87.5% of infections among study participants.
• Hospital study (Sharma et al., 2023): K. pneumoniae sensitivity to meropenem decreased from 15% (2018) to 2.5% (2022), and sensitivity to colistin from 96% (2018) to 28% (2022).
• Key drivers summarized: widespread misuse/overuse of antibiotics, over-the-counter access without prescription, antibiotic use in animal farming (growth promotion and prophylaxis) leading to residues, and inadequate water, sanitation, and hygiene (WASH) increasing infection burden and antibiotic use.
• Contextual patterns: Urban areas face overcrowding and potential pharmaceutical waste pollution; rural areas face limited healthcare access, lower awareness, unregulated OTC antibiotic sales, and substantial agricultural antibiotic use. Migration between rural and urban areas facilitates spread of resistant organisms.
• Sectoral differences: Private sector may over-prescribe and has access to broader antibiotic formularies; public sector faces resource constraints, high patient loads, weaker infection control in some facilities, and populations with prior non-prescription antibiotic exposure.
• Strategic responses outlined (Table 2): strengthen regulation of antibiotic use/production/disposal; invest in diagnostic and healthcare infrastructure; public education on appropriate use; improve AMR surveillance across sectors; public–private collaboration; urban strategies to curb pharmaceutical pollution and over-prescription; rural strategies to improve access and stewardship education; promote R&D of new antibiotics and alternatives; international collaboration.

The evidence and contextual analysis demonstrate that AMR in India is driven by intersecting clinical, community, agricultural, environmental, and policy factors. The reported declines in susceptibility among K. pneumoniae, E. coli, and high resistance in A. baumannii illustrate shrinking treatment options and increased risk of therapeutic failure. Differentiating urban versus rural and private versus public healthcare dynamics helps target interventions: reducing pharmaceutical pollution and stewardship in cities and private care, and bolstering access, infection control, and education in rural and public settings. The proposed multi-pronged strategy aligns with WHO/ICMR priorities, emphasizing regulation, surveillance, diagnostics, stewardship, and innovation to curb resistance and preserve antimicrobial efficacy.

This editorial synthesizes national surveillance data and recent studies to highlight the worsening AMR landscape in India, identifies key drivers across settings, and proposes a comprehensive, context-sensitive strategy. Main contributions include collating current resistance trends, articulating sectoral and geographic drivers, and outlining actionable policy and practice recommendations. Future efforts should prioritize building robust national surveillance, enforcing regulations across human, animal, and environmental domains, scaling stewardship and public education, evaluating intervention effectiveness, and investing in R&D for new antimicrobials and alternative therapies.

As a narrative editorial, findings rely on secondary data and selected reports rather than primary empirical analysis. The paper notes gaps in India’s robust AMR surveillance, making the true burden difficult to ascertain and potentially limiting generalizability. Enforcement of regulations on antibiotic use, production, and disposal remains inconsistent, and environmental contamination from pharmaceutical waste may be under-characterized. These constraints affect the completeness and precision of conclusions.